<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306929</url>
  </required_header>
  <id_info>
    <org_study_id>ACR16C015</org_study_id>
    <nct_id>NCT01306929</nct_id>
  </id_info>
  <brief_title>Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease</brief_title>
  <acronym>OPEN-HART</acronym>
  <official_title>A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prilenia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prilenia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in&#xD;
      movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized&#xD;
      by chorea (involuntary movements) and a progressive loss of voluntary movement causing a&#xD;
      substantial functional impairment over time. The study will assess the long-term safety of&#xD;
      pridopidine and the treatment effects during long-term, open-label treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">January 5, 2018</completion_date>
  <primary_completion_date type="Actual">January 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with at least one adverse event</measure>
    <time_frame>On average 2 years</time_frame>
    <description>Long-term safety profile of pridopidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score</measure>
    <time_frame>On average 2 years</time_frame>
    <description>UHDRS development during long-term, open-label treatment of pridopidine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>pridopidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pridopidine</intervention_name>
    <description>45mg bid</description>
    <arm_group_label>pridopidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able to, and has provided written Informed Consent prior to any study&#xD;
             related procedure.&#xD;
&#xD;
          -  Patient has completed the HART (ACR16C009) or the PRIDE-HD (TV7820- CNS-20002) studies&#xD;
             and had remained on IMP during the full on-treatment part of the study (including&#xD;
             de-escalated patients) or has transitioned from the Open-HART pre-virtualization study&#xD;
             period.&#xD;
&#xD;
          -  Willing and able to take oral medication and able to comply with the study specific&#xD;
             procedures.&#xD;
&#xD;
          -  Patient has a wireless internet connection at home (and/or applicable locations) at&#xD;
             the first remote visit.&#xD;
&#xD;
          -  Patient has the ability to transition from in-person study visits to virtual study&#xD;
             visits. The first remote visit (RV1) will take place within approximately 30 days&#xD;
             after the last in-person visit.&#xD;
&#xD;
               -  Additional criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing treatment with tetrabenazine or deutetrabenazine, seizure threshold lowering&#xD;
             medications, or certain antipsychotics and antidepressants.&#xD;
&#xD;
          -  Newly instigated or changed treatment with neuroleptics/antipsychotics&#xD;
&#xD;
          -  Use of tricyclic antidepressants or class I &amp; III antiarrhythmics at any time during&#xD;
             the study period.&#xD;
&#xD;
          -  Severe intercurrent illness that, in the opinion of the Investigator (or qualified&#xD;
             designee), may put the subject at risk when continuing participation in the study.&#xD;
&#xD;
          -  Alcohol and/or drug abuse as defined by the Diagnostic and Statistical Manual - Fourth&#xD;
             Edition - Text Revision criteria for substance abuse - this includes the illicit use&#xD;
             of cannabis.&#xD;
&#xD;
          -  Subjects with a known history of epilepsy or a history of febrile seizure(s) or&#xD;
             seizure(s) of unknown cause.&#xD;
&#xD;
          -  Females who are pregnant or lactating.&#xD;
&#xD;
          -  Females who are of child bearing potential and not taking adequate contraceptive&#xD;
             precautions (either oral, barrier or chemical contraceptives) are excluded from the&#xD;
             trial. Females of child bearing potential taking acceptable contraceptive precautions&#xD;
             can be included.&#xD;
&#xD;
          -  Known allergy to any ingredients of the trial medication.&#xD;
&#xD;
               -  Additional criteria apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Kieburtz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 045</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 024</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 028</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 037</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 001</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 089</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 018</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 220</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 048</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 231</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 118</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 039</name>
      <address>
        <city>Toronto</city>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington Disease.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

